479 6. Complicanze tardive Bibliografia [1] F. L. Dignan et al., «Diagnosis and management of chronic graft-versus-host disease», Br. J. Haematol., vol. 158, n. 1, pagg. 46–61, lug. 2012, doi: 10.1111/j.1365-2141.2012.09128.x. [2] E. Rostagno et al., «Phototherapy and topical treatments for cutaneous graft vs. host disease in haematopoietic stem cell transplantation patients: a scoping review», J. Eur. Acad. Dermatol. Venereol., pag. jdv.18074, mar. 2022, doi: 10.1111/jdv.18074. [3] Y. J. Kim, G. H. Lee, B. Y. Kwong, e K. J. Martires, «Evidence-based, Skin-directed Treatments for Cutaneous Chronic Graft-versus-host Disease», Cureus, dic. 2019, doi: 10.7759/cureus.6462. [4] N. M. Teske e H. T. Jacobe, «Phototherapy for sclerosing skin conditions», Clin. Dermatol., vol. 34, n. 5, pagg. 614–622, set. 2016, doi: 10.1016/j.clindermatol.2016.05.012. [5] V. Patra, I. Gallais Sérézal, e P. Wolf, «Potential of Skin Microbiome, Pro- and/or Pre-Biotics to Affect Local Cutaneous Responses to UV Exposure», Nutrients, vol. 12, n. 6, pag. 1795, giu. 2020, doi: 10.3390/nu12061795. [6] C. D. V. Villarreal, J. C. S. Alanis, J. C. J. Pérez, e J. O. Candiani, «Cutaneous graft-versus-host disease after hematopoietic stem cell transplant - a review», An. Bras. Dermatol., vol. 91, n. 3, pagg. 336–343, giu. 2016, doi: 10.1590/abd1806-4841.20164180. [7] K. B. Garbutcheon-Singh e P. Fernández-Pe as, «Phototherapy for the treatment of cutaneous graft versus host disease: Phototherapy treatment», Australas. J. Dermatol., vol. 56, n. 2, pagg. 93–99, mag. 2015, doi: 10.1111/ajd.12191. [8] S. Kavand, J. S. Lehman, S. Hashmi, L. E. Gibson, e R. A. elAzhary, «Cutaneous manifestations of graft-versus-host disease: role of the dermatologist», Int. J. Dermatol., vol. 56, n. 2, pagg. 131–140, feb. 2017, doi: 10.1111/ijd.13381. [9] K. Strong Rodrigues, C. Oliveira-Ribeiro, S. de Abreu Fiuza Gomes, e R. Knobler, «Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment», Am. J. Clin. Dermatol., vol. 19, n. 1, pagg. 33–50, feb. 2018, doi: 10.1007/s40257-017-0306-9. [10] R. Ballester-Sánchez, M. Á. Navarro-Mira, B. de Unamuno-Bustos, C. Pujol-Marco, J. Sanz-Caballer, e R. Botella-Estrada, «The Role of Phototherapy in Cutaneous Chronic Graft-vs-Host Disease: A Retrospective Study and Review of the Literature», Actas Dermo-Sifiliográficas Engl. Ed., vol. 106, n. 8, pagg. 651–657, ott. 2015, doi: 10.1016/j.adengl.2015.07.020. [11] D. Wolff et al., «Consensus Conference on Clinical Practice in Chronic Graft-versus-Host Disease (GVHD): First-Line and Topical Treatment of Chronic GVHD», Biol. Blood Marrow Transplant., vol. 16, n. 12, pagg. 1611–1628, dic. 2010, doi: 10.1016/j.bbmt.2010.06.015. [12] T. Gambichler e L. Schmitz, «Ultraviolet A1 Phototherapy for Fibrosing Conditions», Front. Med., vol. 5, pag. 237, ago. 2018, doi: 10.3389/fmed.2018.00237. [13] E. Sorenson, R. McAndrew, V. Patel, A. C. Logan, J. Koo, e E. Levin, «Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease», JAMA Dermatol., vol. 151, n. 6, pag. 635, giu. 2015, doi: 10.1001/jamadermatol.2015.0175. [14] Ø. Bruserud et al., «Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies», Cancer Immunol. Immunother., vol. 63, n. 8, pagg. 757–777, ago. 2014, doi: 10.1007/s00262-014-1578-z. [15] S. Dhir, M. Slatter, e R. Skinner, «Recent advances in the management of graft-versus-host disease», Arch. Dis. Child., vol. 99, n. 12, pagg. 1150–1157, dic. 2014, doi: 10.1136/archdischild-2013-304832. [16] L. Kaynar et al., «Extracorporeal photopheresis in the treatment of acute and chronic graft-versus-host disease: A position statement from the Turkish Society of Apheresis (TSA)», Transfus. Apher. Sci., vol. 61, n. 1, pag. 103373, feb. 2022, doi: 10.1016/j. transci.2022.103373. [17] S. Mohammadi, A. Malek Mohammadi, A. H. Norooznezhad, F. Heshmati, K. Alimoghaddam, e A. Ghavamzadeh, «Extra corporeal photochemotherapy in steroid refractory graft versus host disease: A review of guidelines and recommendations», Transfus. Apher. Sci., vol. 56, n. 3, pagg. 376–384, giu. 2017, doi: 10.1016/j. transci.2017.01.006. [18] M. Nygaard, S. Wichert, G. Berlin, e F. Toss, «Extracorporeal photopheresis for graft-vs-host disease: A literature review and treatment guidelines proposed by the Nordic ECP Quality Group», Eur. J. Haematol., vol. 104, n. 5, pagg. 361–375, mag. 2020, doi: 10.1111/ejh.13381. [19] A. Magarò, B. Lucchetti, A. Caime, M. T. Lionetti, e D. Laszlo, «Cost comparison of extracorporeal photopheresis technologies at the European Institute of Oncology», J. Clin. Apheresis, vol. 36, n. 3, pagg. 364–369, giu. 2021, doi: 10.1002/jca.21870. [20] N. Piccirillo et al., «Inline and offline extracorporeal photopheresis: Device performance, cell yields and clinical response», J. Clin. Apheresis, vol. 36, n. 1, pagg. 118–126, feb. 2021, doi: 10.1002/jca.21851. [21] W. Mayer, A. Kontekakis, C. Maas, U. Kuchenbecker, S. Behlke, e H. Schennach, «Comparison of procedure times and collection efficiencies using integrated and multistep nonintegrated procedures for extracorporeal photopheresis», J. Clin. Apheresis, pag. jca.21974, feb. 2022, doi: 10.1002/jca.21974. [22] L. Pierelli, A. Bosi, e A. Olivieri, «“Best practice” for extracorporeal photopheresis in acute and chronic graft-versus-host disease by Societa’ Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of applica: SURVEY FOR ECP “BEST PRACTICE”», Transfusion (Paris), vol. 58, n. 1, pagg. 217– 222, gen. 2018, doi: 10.1111/trf.14400. [23] V. Radojcic, M. A. Pletneva, e D. R. Couriel, «The role of extracorporeal photopheresis in chronic graft-versus-host disease», Transfus. Apher. Sci., vol. 52, n. 2, pagg. 157–161, apr. 2015, doi: 10.1016/j.transci.2015.02.002. [24] I. Abu-Dalle et al., «Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies», Biol. Blood Marrow Transplant., vol. 20, n. 11, pagg. 1677–1686, nov. 2014, doi: 10.1016/j.bbmt.2014.05.017. [25] J. Schneiderman, «Extracorporeal photopheresis: cellular therapy for the treatment of acute and chronic graft-versushost disease», Hematology, vol. 2017, n. 1, pagg. 639–644, dic. 2017, doi: 10.1182/asheducation-2017.1.639. [26] A. Cho, C. Jantschitsch, e R. Knobler, «Extracorporeal Photopheresis—An Overview», Front. Med., vol. 5, pag. 236, ago. 2018, doi: 10.3389/fmed.2018.00236. [27] R. Tziortzioti, «Extracorporeal Photopheresis for Non-skin GvHD», pag. 2. [28] H. T. Greinix, N. Worel, U. Just, e R. Knobler, «Extracorporeal photopheresis in acute and chronic graft-versus-host disease», Transfus. Apher. Sci., vol. 50, n. 3, pagg. 349–357, giu. 2014, doi: 10.1016/j.transci.2014.04.005. [29] M. Mankarious, N. C. Matthews, J. A. Snowden, e A. Alfred, «Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD)», Front. Immunol., vol. 11, pag. 81, gen. 2020, doi: 10.3389/fimmu.2020.00081. [30] I. Pamler et al., «Bacterial contamination rates in extracorporeal photopheresis», Transfusion (Paris), vol. 60, n. 6, pagg. 1260–1266, giu. 2020, doi: 10.1111/trf.15801. [31] C. Rushton, A. Jackson, K. Goddard, e A. Alfred, «A case review of a patient experience of photopheresis using a peripherally inserted central catheter», J. Clin. Apheresis, vol. 34, n. 1, pagg. 73–74, feb. 2019, doi: 10.1002/jca.21674. [32] J. Adamski, «Vascular access considerations for extracorporeal photopheresis: Access Options For ECP», Transfusion (Paris), vol. 58, pagg. 590–597, feb. 2018, doi: 10.1111/trf.14500. [33] H. Michell, N. Nezami, C. Morris, e K. Hong, «Dual-chambered venous access port as alternative access for extracorporeal apheresis therapy», J. Vasc. Access, vol. 22, n. 2, pagg. 173–177, mar. 2021, doi: 10.1177/1129729820932425. [34] K. Schwede, S. Nagel, J.-C. Simon, e M. Ziemer, «How to perform extracorporeal photopheresis via port catheter: ECP VIA PORT CATHETER», Transfusion (Paris), vol. 57, n. 11, pagg. 2567– 2570, nov. 2017, doi: 10.1111/trf.14265.
RkJQdWJsaXNoZXIy ODUzNzk5